Market Overview

Tekmira Up 4% On Positive Ebola-Related Drug Study

Share:
Related TKMR
The 3 Best Biotech Stocks Of The Last 30 Days
Tekmira Pharmaceuticals, Lakeland Industries Moving On Possible Ebola Case In California

Tekmira Pharmaceuticals (NASDAQ: TKMR) shares gained more than four percent after it was reported that one of its drugs showed promising results in animal studies directed at treating Ebola virus disease.

A peer-reviewed study published Wednesday found that Tekmira's lipid nanoparticle provided "complete protection" in monkeys against Marburg virus infection, the symptoms of which are indistinguishable from Ebola.

The drug appeared effective even when administered up to three days following exposure to the virus, which is closely related to Ebola, the company said.

Related Link: Time To Take Another Look At Tekmira

Results in the journal Science Translational Medicine, were trumpeted in a company press release at 2 p.m. Wednesday and later reported, including in the print edition of Thursday's New York Times.

Tekmira's similar development drug, called TKM-Ebola, got a boost August 7 when regulators modified a clinical hold on the drug to a modified hold, potentially clearing the way for human trials.

Regulators halted a Phase I study of TKM-Ebola on July 3 over safety concerns.

Tekmira traded recently at $18.51, up 4.4 percent.

Posted-In: News Health Care FDA Hot Intraday Update General

 

Related Articles (TKMR)

Around the Web, We're Loving...

Get Benzinga's Newsletters

Our Experts vs. S&P 500Powered by Benzinga
Marketfy Products Return S&P 500
Morning Profit Maker 42.72% 6.69%
The Option Prophet 91.14% 6.69%
SecretCaps 26.55% 6.69%
Short-Term Trend Trading 11.89% 6.69%
View the highest rated products→